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Abstract  
Decision making for not transplant eligible patients with multiple myeloma is complicated by lacking 
head-to-head comparisons of standards of care, increasing treatment modalities and rapidly evolving 
promising results of studies with novel regimens. To support evidence-based decision making, we 
performed a network meta-analysis for not transplant-eligible multiple myeloma patients that 
synthesizes direct and indirect evidence and enable a comparison of all treatments. Relevant 
randomized clinical trials were identified by a systematic literature review in EMBASE®, 
MEDLINE®, MEDLINE®-in-Process and the Cochrane Central Register of Controlled Trials for 
January-1999 to March-2016. Efficacy outcomes (i.e. the hazard ratio and 95% confidence interval 
for progression-free survival) were extracted and synthesized in a random effects network-meta 
analysis. In total 24 studies were identified including 21 treatments.  According to the network-meta 
analysis, the hazard ratio for progression-free survival was favorable for all not transplant-eligible 
myeloma treatments compared to dexamethasone (hazard ratios between 0.19-0.90). Daratumumab-
bortezomib-melphalan-prednisone and bortezomib-melphalan-prednisone-thalidomide with 
bortezomib-thalidomide maintenance were identified as the most effective treatments (hazard ratio: 
0.19 (95% confidence interval 0.08-0.45) and 0.22 (95% confidence interval 0.10-0.51), respectively).  
The hazard ratios and 95% confidence interval for currently recommended treatments, bortezomib-
lenalidomide-dexamethasone, bortezomib-melphalan-prednisone, and lenalidomide-dexamethasone 
compared to dexamethasone, were 0.31 (0.16-0.59), 0.39 (0.20-0.75) and 0.44 (0.29-0.65), 
respectively. In addition to identifying the most effective treatment options, we illustrate the 
additional value and evidence of network meta-analysis in clinical practice. In the current treatment 
landscape, the results of network meta-analysis may support evidence based decisions and ultimately 
help to optimize treatment and outcomes of not transplant eligible multiple myeloma patients. 
 
Ethics committee approval 
Not applicable.  
  
Introduction 
Multiple myeloma (MM) is a hematological disease characterized by the proliferation of malignant 
plasma cells, causing disease-related symptoms such as anemia, hypercalcemia, renal and bone 
disease. The age standardized incidence rate is 4.5 per 100,0001. Incidence increases with age and 
two-thirds of the patients diagnosed with MM are above 65 years2. The treatment armamentarium 
greatly increased in the last decade, with novel proteasome inhibitors (PI’s), immunomodulatory 
drugs (IMiD’s), and monoclonal antibodies now being incorporated in first line treatment regimens, 
which considerably improved progression-free survival (PFS) and overall survival (OS) of MM.  
Given the median age of 70 years at diagnosis, the majority of newly diagnosed (ND) MM patients 
are not eligible for SCT (NTE). Current standards of care for NTE NDMM patients are bortezomib-
melphalan-prednisone (VMP), lenalidomide-dexamethasone (Rd), and in the USA bortezomib-Rd 
(VRd)3, supported by randomized phase III trials4-6. Recently, better PFS was demonstrated for 
Daratumumab-VMP (DaraVMP) compared to VMP7.   
Although randomized clinical trials (RCTs) remain the gold standard to define standards of care, we 
predict that in the current treatment landscape the role of network meta-analysis (NMA) will become 
increasingly important. Firstly, currently there is more than one standard of care, but a randomized 
study between two registered standards of care is highly unlikely to be performed, because of 
reluctance of pharmaceutical industries to support such studies8. Therefore, head-to-head comparisons 
of VMP versus Rd or VRd versus VMP are not likely to be initiated9. NMA can help to discriminate 
between efficacy of non-head-to-head compared regimens. Secondly, with the growing possibilities of 
treatment modalities, the number of smaller randomized phase II studies is expected to increase at the 
cost of phase III RCTs. NMA provide more solid estimates of treatment effects by combining RCTs 
that provide direct and indirect evidence for effectiveness and enable a ranking of competing 
treatments10. Thirdly, with the current high number of accruing studies, standard of care arms are 
expected to change within short times frames8. This hampers the development of classical phase III 
trials, as at the end of the study, it might appear the standard arm of the study does not reflect clinical 
reality anymore. Lastly, the heterogeneous biological characteristics of MM and clonal evolution of 
  
the disease will lead to studies with a smaller sample size that will not allow randomization, 
increasing the need for indirect comparisons.   
There are currently two systematic literature reviews (SLRs) and NMAs available for first-line NTE 
NDMM treatments11,12. Due to the timing of their searches and selection criteria, these reviews did 
not, however, include all currently available treatments (e.g. VRd, VMPT-VT, DaraVMP) and RCT 
evidence (e.g. HOVON87 comparing MPT-T and MPR-R13). To support evidence-based decision 
making in clinical practice, we performed a SLR and NMA synthesizing all direct and indirect 
evidence from phase III RCTs that is currently available and compared the outcome of all treatment 
options for NTE NDMM patients. 
  
Methods 
Systematic literature review 
A SLR was conducted in the databases EMBASE®, MEDLINE®, MEDLINE®-in-Process and the 
Cochrane Central Register of Controlled Trials for the period 01 January 1999 to 01 March 2016 to 
identify relevant studies (Appendix 1). Studies were included if they described a phase III RCT 
among newly diagnosed adult patients with MM. Furthermore, one of the pre-specified treatments 
(Appendix 2) had to be part of the regimens of the RCT. After removing duplicates, citations were 
first screened on title and abstract and then screened on the contents of their full text. Citations were 
excluded due to the following reasons: non-English, review, study phase, intervention, disease, study 
design, meta-analysis, patient population, economic outcomes, meta-analysis, and other (for a detailed 
description of the exclusion categories see Appendix 2). To incorporate the latest clinical 
developments, the publication of the pre-specified interim analysis of the phase III ALCYONE RCT 
comparing DaraVMP to VMP7, was added as additional record.  
Data extraction 
  
Data were extracted on trial details (i.e. publication source, trial ID, trial number, research, and 
comparator treatment(s), number of patients, median age, and primary outcome, and follow-up) and 
efficacy outcomes. Efficacy outcomes included PFS and OS. For OS we obtained median survival. 
For PFS we obtained the median survival, 95% confidence interval (CI) and hazard ratio (HR) and 
95% CI of the HR.  In case HRs and/or 95% CI for PFS were not reported, we estimated the missing 
data with the available Kaplan-Meier curves using the methods described by Tierney et al.14 The most 
recent published PFS data were extracted in case multiple sources reported on one trial. Risk of bias 
in randomized trials was assessed using the Cochrane Collaboration’s tool15 (Appendix 3).  
Network meta-analysis 
A network was made from the identified treatment options in the SLR. It includes the HRs for PFS 
from the trials for treatments that were head-to-head compared. A comparison between all treatments 
can be made based on a common comparator (i.e. reference treatment). The choice of the reference 
treatment does not influence the outcomes of the study and final results can be presented relative to all 
included treatments. The oldest treatment (i.e. dexamethasone) was selected as a reference treatment 
from which the relative effectiveness of all treatments was estimated. We performed a similar analysis 
with MPT as reference treatment, concerning the fact that this regimen was used as (comparator) 
treatment in several RCTs. Treatments were sorted based on their P-score. This P-score measures the 
average proportion of treatments worse than the respective treatment where 1 means theoretically best 
and 0 means worst16. 
To conduct a NMA for two- and multi-arm studies, we used the netmeta package version 0.9-7 in R 
version 3.3.1 (Appendix 4). We ran a random effects model assuming that the included studies 
represent a random sample of effect sizes that could have been observed and that the effect can best 
be estimated by the mean of all available studies. A random effects model was deemed appropriate 
since there were multiple trials available for some comparisons (e.g. MPT with MP) and sampling 
error was not considered to be the most plausible explanation for the observed variation. With a 
random effects model we allow for differences in the patient population and implementations of 
interventions17. The netmeta package uses a frequentist approach based on the graph-theoretical 
  
methods routinely applied in electrical networks18,19. In contrast to the Bayesian approach that 
produces credible intervals, analysis based on the frequentist approach produces 95% CIs and, as all 
CIs, these should be interpreted as follows; 95% of the produced CIs would contain the true value if 
the analysis would be repeated many times20. 
Face-validity of the NMA results was checked by comparing the computed HRs by the NMA with the 
HRs reported in the publications of the trials. To validate our outcomes to a previously reported 
NMA12, we performed a scenario analysis with different treatment groups (separating MPT and MPT-
T) and a scenario with a limited number of studies. In the third scenario analysis we used a fixed 
effect model instead of a random effects model. Heterogeneity and inconsistency were assessed by 
decomposing the Q statistic21,22 and quantified by the I2-statistic23, which presents the percentage of 
the variability in effects due to heterogeneity rather than chance24.  
Results 
Systematic literature review 
Figure 1 presents the PRISMA flow diagram, the PRISMA checklist is presented in Appendix 3. The 
SLR identified in total 19,773 citations from the databases. One additional recent record was included 
(i.e. the ALCYONE trial7). After removing duplicates, 18,752 citations remained. Based on title and 
abstract, 17,741 citations were excluded for further analysis. The full text of 1,011 citations were 
reviewed and based on this assessment 944 citations were excluded. In the second full text review of 
the remaining 67 citations, 43 citations were excluded because these did not report the most recent 
results (e.g. extended follow-up results were available). After the entire assessment, 24 RCTs 
remained and were included for data extraction and the NMA. See Figure 1 for the detailed reasons 
for exclusion. 
 
These 24 RCTs included 21 treatment options: 1) Dexamethasone (D), 2) Dexamethasone-Interferon 
alpha (DI), 3) Melphalan 100 (M100), 4) Melphalan-Dexamethasone (MD), 5) Melphalan-Prednisone 
(MP), 6) Thalidomide-Dexamethasone (TD), 7) Cyclophosphamide-Thalidomide-Dexamethasone 
  
(CTD), 8) Cyclophosphamide-Thalidomide-Dexamethasone (attenuated) (CTD(a)), 9) Melphalan-
Prednisone-Thalidomide / Melphalan-Prednisone-Thalidomide and Thalidomide maintenance 
(MPT/MPT-T), 10) Bortezomib-Dexamethasone (VD), 11) Bortezomib-Thalidomide-Dexamethasone 
(VTD), 12) Bortezomib-Melphalan-Prednisone (VMP), 13) Bortezomib-Thalidomide-Prednisone 
(VTP), 14) Bortezomib-Melphalan-Prednisone-Thalidomide and Bortezomib-Thalidomide (VMPT-
VT), 15) Cyclophosphamide-Prednisone-Lenalidomide (CPR), 16) Lenalidomide-Dexamethasone 
(Rd), 17) 18 cycles Lenalidomide-Dexamethasone (Rd18), 18) Melphalan-Prednisone-Lenalidomide 
(MPR), 19) Melphalan-Prednisone-Lenalidomide and Lenalidomide maintenance (MPR-R), 20) 
Bortezomib-Lenalidomide-Dexamethasone (VRd), 21) Daratumumab-Bortezomib-Melphalan-
Prednisone (DaraVMP), 
Data Extraction 
Table 1 provides the details, extracted, and calculated data of the included trials. Most trials (N=21 
out of 24) investigated iMIDs-based regimens (thalidomide or lenalidomide). Since MP has been the 
standard treatment for decades25, MP was the comparator in 12 trials. PFS was the primary endpoint 
for 13 trials. The median age of the patient population was reported by most trials and ranged from 64 
to 79. While some trials included patients aged <65 years either because of choosing broader age 
limits or because of including patients who were not eligible for SCT independent of age, most trials 
only included patients aged ≥65 years. The IFM99-0626 and IFM01/0127 only focused on patients aged 




All identified RCTs (N=24) and treatments (N=21) were incorporated within one network (Figure 2). 
We combined MPT and MPT-T. The duration of induction therapy with thalidomide varied, leading 
to a clear overlap in planned thalidomide use between protocols with and without maintenance, 
preventing to clearly discriminate between MPT with and without thalidomide maintenance.  
  
 
Figure 2 presents the obtained HR(s) from the trial(s) and the HR obtained from the NMA for each of 
the connections (i.e. treatment comparisons) in our network. In order to validate our data, we 
compared the HR from treatments for which only direct evidence from a single RCT was available. 
The HR obtained from the NMA should be equal to the HR obtained from the RCT. The HR from the 
NMA was  indeed similar to the HR from the trials for six comparisons5-7,28-30 (i.e. CTD(a) vs. MP, 
VMP vs. MP, DaraVMP vs. VMP, VRd vs Rd, VMPT-VT vs. VMP and VMP vs. VTP) (Appendix 
5). In addition, our network includes several treatments for which both direct and indirect evidence 
were available. Appendix 5 presents the HRs based on direct and indirect evidence and shows that 
none of the p-values for disagreement was smaller than 0.05.  
The percentage of the variability in effect estimates due to heterogeneity rather than sampling error 
(=I2) was 72% indicating substantial between-study heterogeneity (i.e. within the 50%-90% range can 
be quantified as substantial heterogeneity24). We allowed for between-study heterogeneity by using 
the random effects model. Heterogeneity could be reduced by excluding some of the trials, however, 
because of a lack of valid reasons (e.g. patient characteristics, treatment dosing or follow-up) for 
excluding trials, we decided not to perform such analyses. 
Results versus dexamethasone  
Figure 3 presents the HRs with the corresponding 95% CI for PFS and the P-score of the NMA in 
which dexamethasone was used as comparator for the remaining 20 “other treatment” options. HRs 
above one indicate that the “other treatment” is less effective than the comparator treatment 
dexamethasone, HRs below one indicate that the “other treatment” is more effective than 
dexamethasone. All first-line NTE NDMM treatment options were better compared to the reference 
treatment dexamethasone (i.e. reduce the risk of progression or death compared to dexamethasone). 
HRs ranged between 0.19-0.90; however, not all treatments were statistically significantly different 
from dexamethasone, because of wide 95% CIs. DaraVMP and VMPT-VT were identified as the 
most effective treatment options as they had the highest and almost similar P-scores (i.e. a 96% and 
93% certainty that this treatment is better than another treatment, averaged over all competing 
  
treatments) and most favorable relative treatment effects compared to dexamethasone (i.e. HR: 0.19, 
95% CI 0.08 to 0.45 and HR 0.22, 95% CI 0.10 to 0.51 for DaraVMP and VMPT-VT, respectively). 
The HRs and 95% CIs for currently recommended treatments, VRd, VMP and Rd compared to 
dexamethasone, were 0.31 (95% CI 0.16-0.59), 0.39 95% CI 0.20-0.75) and 0.44 (0.29-0.65), 
respectively. Selecting MPT as a reference treatment does not change the hierarchy of the treatments 
as the P-score values do not change if one considers a different reference treatment. Compared to 
MPT, only DaraVMP had a statistically lower HR for PFS (HR 0.41 95% CI 0.19-0.91, p-value 
<0.05) (Appendix 6). 
Scenario analysis NMA 
In order to rule out that grouping of MPT and MPT-T would affect the outcome of the analysis, we 
performed a scenario in which we grouped IFM 01/01, IFM 99/06 and Sacchi et al. 2011 as MPT and 
GIMEMA, HOVON49, TMSG and NMSG as MPT-T. The MPT-T group was connected in the 
network to the MPT-T arm from the HOVON87 trial and the ECOG E1A06 trial. Overall, the results 
were comparable to the base case (Appendix 7). We found similar results for MPT (HR 0.46 95% CI 
0.30-0.71) and MPT-T (HR 0.47 95% CI 0.30-0.73) compared to D.  
The second scenario, based on the trials included by Weisel et al.12 showed lower HRs for PFS for Rd 
compared to VMP, MPT and MP but the 95% CI for VMP was overlapping with Rd (Rd vs. VMP HR 
0.73, 95% CI 0.48-1.11 (Appendix 8)).  
Results from the third scenario analysis (fixed effect model instead of random effects model) are 
presented in Appendix 9. While the HRs from the fixed effect model are rather similar, the 95% CIs 
are typically smaller for fixed effect models.  
 
Discussion 
Current clinical decision making in MM is complicated by lacking head-to-head comparisons of 
standards of care, an increasing number of treatment modalities and rapidly evolving promising 
results of studies with novel regimens (among smaller sub populations). In this treatment landscape, 
  
we believe the role of NMA will become increasingly important, although it cannot replace RCTs that 
still remain the gold standard.  
 
Firstly, NMAs are able to provide data where head-to-head comparisons are lacking20,24. For NTE 
NDMM, head-to-head comparisons from the current three standard of care regimens (i.e. VRd, VMP 
and Rd) are lacking. Only VRd has been head-to-head compared to Rd but there are no studies 
comparing VMP with VRd or Rd. With our NMA, we show that the HR of VRd was lower as 
compared to VMP and Rd, and VRd also had the highest P-Score. We present similar HRs and P-
Scores for VMP and Rd. However, we also show considerable overlap of the 95% CIs of VRd, Rd 
and VMP. Our NMA does not support the use of one over the other regimens, leaving three valuable 
options for clinical practice. The choice of therapy will be guided by characteristics of the patient and 
the, such as a PI-based regimen in high risk cytogenetic disease and a preference for lenalidomide 
without bortezomib in patients with neuropathy31-34. 
According to the ranking based on their P-scores and comparative effectiveness estimates, DaraVMP 
and VMPT-VT were identified as the most effective treatments. Although there is a RCT already 
showing better PFS and OS28 for VMPT-VT when compared with VMP, we now add data showing 
comparable efficacy to DaraVMP, which is expected to become an important standard of care. This 
finding is of importance given the pronounced differences in global access to costly treatment 
regimens. As all drugs in the VMPT-VT regimen will soon be available as generic compounds, this 
regimen is a valuable option in clinical practice as well. In addition, the pronounced efficacy of 
VMPT-VT highlights the use of maintenance therapy following PI-based induction regimens. Also 
the study of the PETHEMA group showed (in a non-head-to-head comparison with VMP) that 
maintenance therapy did result in a substantial longer PFS35. We now add further evidence for 
maintenance therapy with PIs by showing high efficacy of VMPT-VT as compared to VMP. This is of 
importance as currently EMA did not approve maintenance therapy with bortezomib, as head-to-head 
comparisons of maintenance versus no maintenance therapy are lacking.  
  
 
Secondly, NMAs provide more solid and precise effectiveness estimates in case head-to-head data 
from multiple RCTs are available20,24. Our network included several trials investigating MPT/MPT-T 
vs. MP.  Some of these trials showed MPT/MPT-T to be superior over MP26,27,36, while other trials 
found no difference37-40. NMA enables synthesizing this evidence and according to our analysis, 
MPT/MPT-T was superior over MP (HR 0.67 95% CI 0.55-0.81). 
 
Third, NMA calculates effectiveness estimates including direct and indirect evidence from RCTs 
providing additional evidence in case head-to-head data from a single RCT only are available. Due to 
the rapid evolvement of the treatment armamentarium, efficacy evidence is increasingly based on a 
single RCT, not seldom from only one institute or region in the world. There is increasing evidence 
for contradictory results of RCTs investigating a similar treatment comparison41 and this may increase 
the interest in indirect evidence. Indirect evidence may confirm or alter the results from a single RCT 
as we showed for MPR-R compared to MPT. Although there was no statistically significant difference 
between MPR-R and MPT-T based on direct evidence from two RCTs, synthesizing direct and 
indirect evidence resulted in a statistically significant HR for MPR-R compared to MPT/MPT-T. 
Favorable indirect evidence for MPR-R compared to MPT-T was obtained through the comparison 
with MP. MPR-R compared more favorable to MP (according to the MM-15 HR MPR-R vs MP 0.4) 
than MPT (HR MPT vs MP 0.67 according to multiple trials). However, it should be noted that the 
direct evidence for MPR-R compared to MP was based on a single RCT while MPT/MPT-T vs MP 
was studied in seven RCTs and therefore the evidence for the latter comparison is believed to be more 
solid24,41. Indirect evidence is not always available, for example for the comparison VRd and Rd there 
is only direct evidence from a single study6. While a fixed effect NMA will produce similar results to 
the trial (HR 0.71 95% CI 0.57-0.9), a random effects NMA obtains larger 95% CIs (HR 0.71 95% CI 
0.43-1.17), as it includes two levels of uncertainty; within and between study variances17. Hence, 
treatments are less likely to differ significantly.  
  
 
Two other NMAs are available for newly diagnosed NTE NDMM patients. Our results align with the 
results from Kuhr et al.11 in that VMP and MPT are more effective than MP. Our results also confirm 
the conclusion from Weisel et al.12 that Rd is more favorable than MP (HR 0.63, 95% CI 0.44-0.89 
(Appendix 5)). However in contrast to their findings, we found that Rd and VMP have comparable 
effectiveness outcomes (i.e., small difference in HR for PFS compared to D but largely overlapping 
CIs). The primary analysis of Weisel et al. included a limited number of treatments (i.e. VMP, MP, 
MPT and Rd) and RCTs (i.e. VISTA, IFM01/01, IFM 99/06, Sacchi, FIRST) as phase III trials not 
using dosing schemes in line with the summary of product characteristics (SmPC) were excluded. 
There are several arguments against this restriction. Firstly, although dosing schemes in line with the 
SmPC might be recommended in the selected trials by Weisel et al., it is debatable whether this 
ensures treatments are identical within a network, especially because of variation in clinical practice 
either due to physicians preference or patient-related factors such as age, co-morbidities and toxicities. 
For example, the trial of Sacchi et al. 2011 was grouped with MPT studies while maintenance was 
provided in a limited number of centers. Furthermore, the administered and planned dose may differ, 
as for example illustrated by the HOVON87 where relative dose intensity varied between 0.54-0.9613. 
Since there is a lack of evidence on the impact of dosing schemes, we believe that a more 
comprehensive network (i.e. our network included 19 additional trials) provides more solid evidence. 
The reason Weisel et al.12 did not found overlap between VMP and Rd in their sensitivity analyses 
including six and twelve additional studies, is most likely because they used a fixed effect model for 
their analysis. A random effects model that was used in our analysis and by Kuhr et al.11 is however, 
more appropriate as this model allows for the between study-heterogeneity in the added studies. 
 
One might argue that while our NMA provides additional evidence in different circumstances, we had 
to make assumptions to conduct the analysis, which introduces a level of uncertainty. First, we 
grouped MPT and MPT-T studies since we could not make an unambiguous distinction between 
  
them. For example, thalidomide was prescribed until disease progression in the HOVON49 and 
GIMEMA trial but prescribed “continuously” for up to a maximum of 12 months in the TMSG trial. 
In the NMSG trial it was even recommended to continue thalidomide maintenance until second 
relapse. However, most investigators discontinued thalidomide at first relapse. Prescription of 
thalidomide was also not consistent within a trial38. Sacchi et al.38  described that, although planned, 
maintenance was only provided to 18% of the patients and in a limited number of centers. Their 
results however, showed that PFS did not differ between maintenance and no-maintenance42. 
Therefore, we believe that combining these trials, as performed previously11,43 is appropriate, and the 
results of our sensitivity analysis confirm this assumption (see Appendix 7).  
Secondly, the validity of the outcomes of NMA depend on the comparability between studies. Our 
analysis focused on treatments for NTE NDMM patients studied in phase III RCTs. Although, 
including non-randomized evidence in NMA is possible45 and could have provided additional 
information regarding effectiveness in clinical practice46-48 or treatments not analyzed in a phase III 
RCT (e.g. bortezomib-cyclophosphamide-dexamethasone; VCD49), we believe that limiting our 
analysis to the relative effectiveness of RCT evidence, reduces the risk of bias and systematic errors44.  
Further research to improve methodologies for conducting, evaluating and interpreting non-
randomized evidence is recommended.44 We focused on NTE NDMM treatment to increase 
homogeneity between the patient populations in the study We observed between-study heterogeneity 
comparable to the proportions previously reported by Kuhr et al.  By using a random effects instead of 
a fixed effect model we allow for this heterogeneity. As a consequence we obtain however, larger 
95% CIs. 
A potential limitation of our search strategy is that we only included English publication. To the best 
of our knowledge this does however not lead to the exclusion of relevant studies or treatments. 
Furthermore, our NMA was limited to the intermediate outcome PFS and did not include other 
outcomes of interest such as OS, adverse events, quality of life, costs, and cost-effectiveness. While 
OS may even be the most important subject of investigation for patients and health care decision 
makers, we believe a comparison of OS for first-line therapies with the currently available data is 
  
prone to bias due to cross-over, different and limited follow-up (e.g. especially for DaraVMP median 
OS was not reached at 16.5 months follow-up)  and subsequent treatment lines50,51. Also cost-
effectiveness, in the context of increasing health care expenditures another relevant and important 
outcome, remains subject for further research. Several treatment options showed comparable 
effectiveness outcomes but costs could very well differ due to drug prices, treatment duration, and 
route of administration. Our study facilitates cost-effectiveness research of first-line NTE treatments.  
 
As the treatment armamentarium is rapidly increasing and evolving for NTE NDMM patients NMAs 
will become increasingly important. We illustrate the additional value and evidence that can be 
provided.  NMAs support evidence based decision making and may help to optimize treatment and 
outcomes of NTE NDMM patients in clinical practice.  
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Table 1 Data extraction of the included trials 
Trial reference 


















Facon 2006 n/r OS 500 D 70 (67-73) 127 12.2 (10.2-14.2)     33.4 82.8 
IFM 95/01       MP 70 (68-72) 122 21.1 (17.8-24.4) 0.75 (0.62-0.91) {MP v D} 1.15 (0.93-1.42) {MP v MD} 34 82.8 
        MD 69 (68-72) 118 22.9 (19.0-26.8) 0.66 (0.53-0.81) {MD v D} 1.45 (1.17-1.79) {DI v MD} 39.6 82.8 
        DI 69 (67-72) 121 15.2 (9.9-20.5) 0.92 (0.76-1.11) {DI v D} 1.26 (1.04-1.53) {DI v MP} 32 82.8 
Facon 2007 NCT00367185 OS 447 MPT n/r (65-75¹) 125 27.5 (23.4-31.6) 0.59 (0.44-0.78) {MPT v M100}   51.6 51.5 
IFM 99–06       MP n/r (65-75²) 196 17.8 (15.1-20.5) 0.51 (0.39-0.66) {MPT v MP}   33.2 51.5 
        M100 n/r (65-75³) 126 19.4 (17.4-21.4) 0.87 (0.68-1.1) {M100 v MP}   38.3 51.5 
Morgan 2013 ISRCTN68454111 PFS, OS 856 MP 73 (57-89) 423 12 n/r 0.81 (0.69-0.94) {CTD(a) v MP}   32 70.8 
MRC M IX       CTDa 73 (58-87) 426 13 n/r     34 70.8 
Rajkumar 2008 NCT00057564 TTP 470 TD 64 (39-86) 235 14.9 n/r 0.5 (0.38-0.64) {TD v D}   NR 17 
MM-003       D 64 (31-84) 235 6.5 n/r     30 18 
Ludwig 2009 NCT00205751 
PFS, 
tolerance 289 TD 72 (54-86) 145 16.7 n/r 1.3 (0.95-1.78) {TD v MP}   41.5 28.1 
        MP 72 (55-86) 144 20.7 n/r     49.4 28.1 
Palumbo 2008 NCT00232934 RR, PFS 331 MPT-T 72  167 21.8 (19.6-26.1) 0.63 (0.48-0.81) {MPT v MP}   45 38.4 
GIMEMA       MP 72  164 14.5 (12.2-17)     47.6 37.7 
Hulin 2009 n/r OS 232 MPT 79 (75-89) 115 24.1 (19.4-29) 0.61 (0.46-0.82) {MPT v MP}   44 47.5 
IFM 01/01 Trial       MP   117 18.5 (14.6-21.3)     29.1 47.5 
Waage 2010 NCT00218855 OS 363 MPT-T 75  184 15 (12-19) 0.89 (0.7-1.13) {MPT v MP}   29 42 
NMSG       MP 74  179 14 (11-18)     32 42 
Beksac 2010 NCT00934154 Treatment 
response, 
toxicities 
122 MPT 69  60 n/r n/r 0.7 (0.42-1.17) {MPT v MP}   26 35 
TMSG     MP 72  62 n/r n/r     28 23 
Wijermans 2010 ISRCTN90692740 EFS 344 MPT-T 72 (65-87) 171 15 n/r 0.79 (0.62-1) {MPT v MP}   40 39 
HOVON-49       MP 73 (65-84) 173 11 n/r     31 39 
Sacchi 2011 n/r n/r 135 MPT 76 (66–89) 70 33 n/r 0.67 (0.38-1.18) {MPT v MP}   52 30 
        MP 79 (68–88) 65 22 n/r     32 30 
Hungria 2016 NCT01532856 ORR 82 CTD 70 32 25.9 n/r 0.89 (0.48-1.64) {MPT v CTD}   32.4 37.5 
        TD 72 18 21.5 n/r 1.1  (0.53-2.31) {TD v CTD}   54.6 37.5 
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        MPT 72  32 38.5 n/r 0.73 (0.34-1.59) {MPT vs TD}   42 37.5 
San Miguel 2008 NCT00111319 TTP 682 VMP 71 (57–90) 344 21.7 n/r 0.56 (0.4-0.79) {VMP v MP}   56.4 60.1 
VISTA       MP 71 (48–91) 338 15.2 n/r     43.1 60.1 
Mateos 2014 NCT00443235 n/r 260 VTP 73 (69–76) 130 23 n/r 0.8 (0.61-1.04) {VMP v VTP}   43 72 
GEM2005       VMP 73 (68–77) 130 32 n/r     63 72 
Niesvizky 2015 NCT00507416 PFS 502 VD 75 (67-79) 168 14.7 (12-18.6) 1.12 (0.83-1.51) {VD v VTD}   49.8 44.3 
UPFRONT       VTD 73  (66-77) 167 15.4 (12.6-24.2) 0.89 (0.66-1.21) {VTD v VMP}   51.5 41.3 
        VMP 72 (68-77) 167 17.3 (14.8-20.3) 1.11 (0.84-1.48) {VD v VMP}   53.1 43.4 
Palumbo 2014 NCT01063179 PFS 511 VMPT-VT 71 (68-75) 254 35.3 n/r 0.58 (0.47-0.71) {VMPT-VT v VMP}   NR 54 
GIMEMA0305       VMP 71 (68-75) 257 24.8 n/r     60.6 54 
Zonder 2011 NCT00064038 PFS 198 RD n/r⁴ 99 39 (26-53) 0.56 (0.39-0.79) {RD v D}   NR 45.4 
S0232       D n/r⁵ 99 15 (8-23)     NR 45.4 
Benboubkher 2014 NCT00689936 PFS 1623 Rd 73 (44–91) 535 25.5 n/r 0.97 (0.83-1.12) {MPT v RD18}   58.9 45.5 
FIRST/MM-020       Rd18 73 (40–89) 541 20.7 n/r 1.43 (1.22-1.67) {RD18 v RD}   56.7 45.5 
        MPT 73 (51–92) 547 21.2 n/r 1.39 (1.18-1.64) {MPT v RD}   48.5 45.5 
Zweegman 2016 
EUDRACT 2007-
004007-34 PFS 568 MPT-T 72 (60-91) 280 20 (18-23) 0.87 (0.72-1.04) {MPR-R vs MPT-T}   49 32.6 
HOVON-87       MPR-R 73 (60-87) 280 22 (19-27)     50 32.6 
Stewart 2015 NCT00602641 PFS 306 MPT-T 76 (54-92) 154 21 (18-27) 0.84 (0.64-1.09) {MPT-T v MPR-R}   52.6 40.7• 
ECOG E1A06       MPR-R 77 (63-92) 152 18.7 (16-22)     47.7 
Magarotto 2016 NCT01093196 PFS 654 MPR-R 74 (63-91) 218 24 n/r 0.81 (0.63-1.03) {MPR-R v RD}   NR 39 
EMN01       CPR 73 (63-87) 222 20 n/r 1.01 (0.9-1.13) {CPR v RD}   NR 39 
        Rd 73 (50-89) 222 21 n/r 0.8 (0.63-1.02) {MPR-R v CPR}   NR 39 
Palumbo 2012 NCT00405756 PFS 459 MPR-R 71 (65–87) 152 31 n/r 0.49 (0.35-0.69) {MPR-R v MPR}   56 53 
MM-015       MP 72 (65–91) 154 13 n/r 1.19 (0.94-1.5) {MP v MPR}   52 53 
        MPR 71 (65–86) 153 14 n/r 0.4 (0.29-0.54) {MPR-R v MP}   54 53 
Durie 2017  NCT00644228 PFS 525 VRd n/r (≥18⁶) 264 43 (39-52) 0.71 (0.56-0.91) {VRd v Rd}   52 54 
SWOG S0777       Rd n/r (≥18⁷) 261 30 (25-39)     38 56 
Mateos 2018 NCT02195479 PFS 706 DaraVMP 71 (40-93) 350 NR   0.50 (0.38-0.65) {DaraVMP v VMP}   NR 16.5 





Legend Table 1 
"  Mean instead of median; n/r: not reported; NR: not reached; PFS: progression-free survival; OS: overall survival; TTP: time to progression; EFS: event-free 
survival; ORR: overall response rate; RR: repsonse rate, CI: confidence interval; C: cyclophosphamide; D/d: dexamethasone; Dara: daratumumab; M: melphalan; 
P: prednisone; R: lenalidomide; T: thalidomide; V: bortezomib"           
  
  Abstract identified from SLR, full text available from december 2016; • Median follow-up from survivors      
  
¹40% ≥70 years ²43% ≥70 years ³39% ≥70 years ⁴49% ≥65 years ⁵47% ≥65 years ⁶38% ≥65 years ⁷48% ≥65 years 
Source HR: from published trial (MM-003, Ludwig 2009, GIMEMA, MRC-MIX, GIMEMA0305, HOVON87, S0777, E1A06, ALCYONE, IFM-99/06, 
EMN01, FIRST ), obtained from a previous patient-level meta-analysis5 (IFM-01/01, NMSG, TMSG, HOVON49), from a previous NMA15 (Sacchi 2011) and 
data on file from investigators (Hungria 2016). Calculations were made using the published HR and P value (VISTA), Kaplan-Meier curves (IFM95/01 and the 
MM-15) and p-value and number of events (GEM2005, Upfront, s0232). Table 1 presents the extracted and calculated data. 
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Figure 1 PRISMA 2009 Flow Diagram – TNEMM phase III RCTs 
 
Figure 2 Network of the included studies in the network meta-analysis 
Legend:  
White boxes represent treatments and reference numbers using the following abbreviations;  
[1] Dexamethasone (D) 
[2] Dexamethasone-Interferon alpha (DI) 
[3] Melphalan 100 (M100) 
[4] Melphalan-Dexamethasone (MD) 
[5] Melphalan-Prednisone (MP) 





[9] Melphalan-Prednisone-Thalidomide / Melphalan-
Prednisone-Thalidomide and Thalidomide 
maintenance (MPT/MPT-T) 
[10] Bortezomib-Dexamethasone (VD) 
[11] Bortezomib-Thalidomide-Dexamethasone 
(VTD) 
[12] Bortezomib-Melphalan-Prednisone (VMP) 
[13] Bortezomib-Thalidomide-Prednisone (VTP) 
[14] Bortezomib-Melphalan-Prednisone-Thalidomide 
and Bortezomib-Thalidomide (VMPT-VT) 
[15] Cyclophosphamide-Prednisone-Lenalidomide 
(CPR) 
[16] Lenalidomide-Dexamethasone (Rd) 
[17] 18 cycles Lenalidomide-Dexamethasone (Rd18) 
[18] Melphalan-Prednisone-Lenalidomide (MPR) 
[19] Melphalan-Prednisone-Lenalidomide and 






Black box represents the reference treatment in the network meta-analysis. 
Grey boxes include the trial reference and hazard ratio for progression-free survival on the top row(s). 
The bottom row shows the hazard ratio according to the network meta-analysis (NMA). 
* (asterisk) indicates hazard ratio not statistically significant at 5% 
 
Figure 3 NMA results in which dexamethasone was used as comparator 
Legend: 
HR: Hazard ratio.  






Appendix 1 Search strategies 
1.1 Embase® and MEDLINE® 
Database name  Embase®/MEDLINE® 
Search interface http://www.embase.com 
Date of search   5 March 2016 
Time segment   16 June 2010 to 01 March 2016 
Search filter - 
 
Table Embase® and MEDLINE® search strategy for randomized controlled trials 
# Search term 
1 'clinical trial'/exp 
2 'randomization'/de 
3 'controlled study'/de 
4 'comparative study'/de 
5 'single blind procedure'/de 
6 'double blind procedure'/de 
7 'crossover procedure'/de 
8 'placebo'/de 
9 'clinical trial' OR 'clinical trials' 
10 'controlled clinical trial' OR 'controlled clinical trials' 
11 'randomised controlled trial' OR 'randomized controlled trial' OR 'randomised controlled trials' OR 'randomized 
controlled trials' 
12 'randomisation' OR 'randomization' 
13 rct 
14 'random allocation' 
15 'randomly allocated' 
16 'allocated randomly' 
17 allocated NEAR/2 random 
18 (single OR double OR triple OR treble) NEAR/1 (blind* OR mask*) 
19 placebo* 
20 'prospective study'/de 
21 #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 
OR #17 OR #18 OR #19 OR #20 
22 'case study'/de 
23 'case report'/de 
24 'abstract report'/de 
25 'letter'/de 
# Search term 
26 #22 OR #23 OR #24 OR #25 
27 #21 NOT #26 
28 'cohort analysis'/exp 
29 'longitudinal study'/exp 
30 'prospective study'/exp 
31 'follow up'/exp 
32 'major clinical study'/exp 
33 'clinical trial'/exp 
34 'clinical article'/exp 
35 'intervention study'/exp 
36 'survival'/exp 
37 cohort*:ab,ti 
38 (('follow up' OR followup) NEXT/1 (study OR studies)):ab,ti 
39 (clinical NEXT/1 trial*):ab,ti 
40 'retrospective study'/exp 
41 'case control study'/exp 
42 (case* NEXT/1 control*):ab,ti 
43 #28 OR #29 OR #30 OR #31 OR #32 OR #33 OR #34 OR #35 OR #36 OR #37 OR #38 OR #39 OR #40 OR #41 OR 
#42 
44 #27 OR #43 
45 'multiple myeloma'/de 
46 'myeloma'/de 
47 'myeloma cell'/de 
48 myelom* 
49 #45 OR #46 OR #47 OR #48 
50 'bortezomib'/de 
51 bortezomib:ab,ti OR velcade:ab,ti OR ps341:ab,ti OR 'ps-341':ab,ti OR (ps NEAR/1 '341'):ab,ti OR (proteasome 
NEXT/1 inhibit*):ab,ti 
52 'lenalidomide'/de 
53 lenalidomide:ab,ti OR revimid:ab,ti OR revlimid:ab,ti OR 'cc 5013':ab,ti OR cc5013:ab,ti OR 'cdc 501':ab,ti OR 'cdc 
5013':ab,ti OR cdc501:ab,ti OR cdc5013:ab,ti OR 'enmd 0997':ab,ti OR enmd0997:ab,ti OR 'imid 3':ab,ti OR imid3:ab,ti 
54 'thalidomide'/de 
55 thalidomide:ab,ti OR thalidomid:ab,ti OR thalimodide:ab,ti OR thalomid:ab,ti OR contergan:ab,ti OR distaval:ab,ti OR 
isomin:ab,ti OR 'k-17':ab,ti OR kedavon:ab,ti OR kevadon:ab,ti OR neurosedin:ab,ti OR neurosedyne:ab,ti OR 'nsc 
66847':ab,ti OR sedalis:ab,ti OR 'shin naito':ab,ti OR softenon:ab,ti OR synovir:ab,ti OR talimol:ab,ti OR talizer:ab,ti 
OR telagan:ab,ti OR telargan:ab,ti 
56 'bendamustine'/de 
57 bendamustine:ab,ti OR 'cimet 3393':ab,ti OR cytostasan:ab,ti OR cytostasane:ab,ti OR 'imet 3393':ab,ti OR 
ribomustin:ab,ti OR treanda:ab,ti 
# Search term 
58 'dexamethasone'/de 
59 'aeroseb dex':ab,ti OR aflucoson*:ab,ti OR anaflogistico:ab,ti OR arcodexan*:ab,ti OR azium:ab,ti OR calonat:ab,ti OR 
cebedex:ab,ti OR colofoam:ab,ti OR cortidron*:ab,ti OR cortisumman:ab,ti OR dacortin*:ab,ti OR dalalone:ab,ti OR 
decacortin:ab,ti OR decadeltoson*:ab,ti OR decadion:ab,ti OR decadr*n*:ab,ti OR decaesadril:ab,ti OR 
decamethasone:ab,ti OR decasone:ab,ti OR decaspray:ab,ti OR decasterolone:ab,ti OR decilone:ab,ti OR decofluor:ab,ti 
OR dectancyl:ab,ti OR dekacort:ab,ti OR delladec:ab,ti OR deltafluoren:ab,ti OR deltafluorene:ab,ti OR dergramin:ab,ti 
OR deronil:ab,ti OR desacort:ab,ti OR desacortone:ab,ti OR desadrene:ab,ti OR desalark:ab,ti OR desameton*:ab,ti OR 
'dexa cortisyl':ab,ti OR 'dexa dabrosan':ab,ti OR 'dexa korti':ab,ti OR 'dexa scherosan':ab,ti OR 'dexa scherozon':ab,ti OR 
'dexa scherozone':ab,ti OR dexachel:ab,ti OR dexacort*:ab,ti OR dexadabroson:ab,ti OR dexadecadrol:ab,ti OR 
dexadrol:ab,ti OR dexagen:ab,ti OR dexahelvacort:ab,ti OR dexakorti:ab,ti OR dexalocal:ab,ti OR dexamecortin:ab,ti 
OR dexameson*:ab,ti OR dexametason*:ab,ti OR dexameth:ab,ti OR dexametha*on*:ab,ti OR dexamethonium:ab,ti OR 
dexan:ab,ti OR dexane:ab,ti OR dexapot:ab,ti OR dexaschero*on*:ab,ti OR dexason*:ab,ti OR dexinoral:ab,ti OR 
dexionil:ab,ti OR dexone:ab,ti OR dextelan:ab,ti OR dezone:ab,ti OR doxamethasone:ab,ti OR esacortene:ab,ti OR 
exadion*:ab,ti OR firmalone:ab,ti OR fluormone:ab,ti OR fluorocort:ab,ti OR fluorodelta:ab,ti OR fortecortin:ab,ti OR 
gammacorten*:ab,ti OR grosodexon*:ab,ti OR hexadecad*ol:ab,ti OR hexadiol:ab,ti OR hexadrol:ab,ti OR isnacort:ab,ti 
OR isoptodex:ab,ti OR isoptomaxidex:ab,ti OR 'lokalison f':ab,ti OR luxazone:ab,ti OR marvidione:ab,ti OR 
maxidex:ab,ti OR mediamethasone:ab,ti OR megacortin:ab,ti OR mephameson*:ab,ti OR metasolon*:ab,ti OR 
methazonion*:ab,ti OR millicorten:ab,ti OR millicortenol:ab,ti OR 'mk 125':ab,ti OR mk125:ab,ti OR 
nisomethasona:ab,ti OR novocort:ab,ti OR 'nsc 34521':ab,ti OR nsc34521:ab,ti OR opticorten:ab,ti OR opticortinol:ab,ti 
OR oradex*n*:ab,ti OR orgadrone:ab,ti OR policort:ab,ti OR posurdex:ab,ti OR prodexona:ab,ti OR prodexone:ab,ti OR 
sanamethasone:ab,ti OR spoloven:ab,ti OR triamcimetil:ab,ti OR visumethazone:ab,ti 
60 'melphalan'/de 
61 melph*lan:ab,ti OR alkeran:ab,ti OR 'cb 3025':ab,ti OR cb3025:ab,ti OR 'levo sarcolysin':ab,ti OR levofalan:ab,ti OR 
melfalan:ab,ti OR melphalon:ab,ti OR 'nsc 8806':ab,ti OR nsc8806:ab,ti OR 'phenylalanine 2037':ab,ti OR 
'phenylalanine mustard':ab,ti 
62 'vincristine'/de 
63 vincristine:ab,ti OR vincristin:ab,ti OR 'l 37231':ab,ti OR l37231:ab,ti OR 'vin cristine':ab,ti OR vincrisul:ab,ti 
64 'cyclophosphamide'/de 
65 cyclophosphamide:ab,ti OR 'b 518':ab,ti OR b518:ab,ti OR carloxan:ab,ti OR clafen:ab,ti OR cycloblastin*:ab,ti OR 
'cyclofos amide':ab,ti OR cyclofosfamid*:ab,ti OR cyclophosphamid*:ab,ti OR cyclophosphan*:ab,ti OR cyclostin:ab,ti 
OR cycloxan:ab,ti OR cyphos:ab,ti OR cytophosphan*:ab,ti OR cytoxan:ab,ti OR 'endocyclo phosphate':ab,ti OR 
end*xan*:ab,ti OR genoxal:ab,ti OR 'mitoxan neosan':ab,ti OR neosar:ab,ti OR noristan:ab,ti OR 'nsc 26271':ab,ti OR 
'nsc 2671':ab,ti OR procytox:ab,ti OR procytoxide:ab,ti OR se*doxan:ab,ti 
66 'doxorubicin'/de 
67 doxorubicin:ab,ti OR adriablastin:ab,ti OR adriablastin*:ab,ti AND adriacin:ab,ti OR adriamicin*:ab,ti OR 
adriblastin*:ab,ti OR caelyx:ab,ti OR doxil:ab,ti OR doxorubicine:ab,ti OR 'fi 106':ab,ti OR fi106:ab,ti OR lipodox:ab,ti 
OR myocet:ab,ti OR 'nsc 123127':ab,ti OR nsc123127:ab,ti OR rastocin:ab,ti OR resmycin:ab,ti OR 'rp 25253':ab,ti OR 
rp25253:ab,ti OR rubex:ab,ti OR sarcodoxome:ab,ti OR 'tlc d 99':ab,ti 
68 'carmustine'/de 
69 carmustine:ab,ti OR bcnu:ab,ti OR bicnu:ab,ti OR carmubis:ab,ti OR carmubris:ab,ti OR carmustin:ab,ti OR gliadel:ab,ti 
OR nitrumon:ab,ti OR 'nsc 409962':ab,ti 
70 'prednisone'/de 
71 prednisone:ab,ti OR ancortone:ab,ti OR biocortone:ab,ti OR colisone:ab,ti OR cortidelt:ab,ti OR 'de cortisyl':ab,ti OR 
decortancyl:ab,ti OR de*ortin*:ab,ti OR dehydrocortisone:ab,ti OR delitisone:ab,ti OR deltacort*n*:ab,ti OR 
deltacortisone:ab,ti OR deltasone:ab,ti OR deltra:ab,ti OR 'di-adreson':ab,ti OR diadreson:ab,ti OR en*orton*:ab,ti OR 
hostacortin:ab,ti OR insone:ab,ti OR meprison:ab,ti OR metacortandracin:ab,ti OR meticorten:ab,ti OR meticortine:ab,ti 
OR 'nsc 10023':ab,ti OR nsc10023:ab,ti OR orasone*:ab,ti OR paracort:ab,ti OR precort:ab,ti OR precortal:ab,ti OR 
prednisone*:ab,ti OR pronizone:ab,ti OR rectodelt:ab,ti OR ultracorten:ab,ti OR urtilone:ab,ti 
72 'prednisolone'/de 
73 prednisolone:ab,ti OR antisolon*:ab,ti OR aprednislon*:ab,ti OR benisolon*:ab,ti OR berisolon*:ab,ti OR 
caberdelta:ab,ti OR 'co hydeltra':ab,ti OR codelcortone:ab,ti OR cortadelton*:ab,ti OR cortelinter:ab,ti OR 
cortisolone:ab,ti OR dacortin:ab,ti OR decortril:ab,ti OR dehydrocortex:ab,ti OR dehydrocortisol*:ab,ti OR 
dehydrohydrocortison*:ab,ti OR delcortol:ab,ti OR deltacortef:ab,ti OR deltacortenolo:ab,ti OR deltacortil:ab,ti OR 
deltacortoil:ab,ti OR deltaderm:ab,ti OR deltaglycortril:ab,ti OR deltahycortol:ab,ti OR deltahydrocortison*:ab,ti OR 
deltaophticor:ab,ti OR deltasolone:ab,ti OR deltastab:ab,ti OR deltidrosol:ab,ti OR deltisilone:ab,ti OR deltisolon*:ab,ti 
# Search term 
OR deltolasson*:ab,ti OR deltoson*:ab,ti OR dicortol:ab,ti OR domucortone:ab,ti OR encort*lon*:ab,ti OR 
glistelone:ab,ti OR hostacortin:ab,ti OR hydeltra:ab,ti OR hydeltrone:ab,ti OR hydrelta:ab,ti OR hydrocortancyl:ab,ti 
OR hydrocortidelt:ab,ti OR hydrodeltalone:ab,ti OR hydrodeltisone:ab,ti OR hydroretrocortin*:ab,ti OR inflanefran:ab,ti 
OR insolone:ab,ti OR keteocort:ab,ti OR leocortol:ab,ti OR mediasolone:ab,ti OR meprisolon*:ab,ti OR 
metacortalon*:ab,ti OR metacortandralon*:ab,ti OR metacortelone:ab,ti OR meticortelone:ab,ti OR metiderm:ab,ti OR 
morlone:ab,ti OR mydrapred:ab,ti OR nisolon:ab,ti OR nisolone:ab,ti OR 'nsc 9120':ab,ti OR nsc9120:ab,ti OR 
panafcortolone:ab,ti OR panafort:ab,ti OR paracortol:ab,ti OR phlogex:ab,ti OR precortalon:ab,ti OR precortancyl:ab,ti 
OR precortisyl:ab,ti OR predartrin*:ab,ti OR prednedome:ab,ti OR prednelan:ab,ti OR prednicoelin:ab,ti OR 
prednicort:ab,ti OR prednicortelone:ab,ti OR prednifor:ab,ti OR predniment:ab,ti OR predniretard:ab,ti OR prednis:ab,ti 
OR prednivet:ab,ti OR prednorsolon*:ab,ti OR predonine:ab,ti OR predorgasolon*:ab,ti OR prelone:ab,ti OR 
prenolone:ab,ti OR prezolon:ab,ti OR scherisolon:ab,ti OR serilone:ab,ti OR solone:ab,ti OR solupren*:ab,ti OR 
spiricort:ab,ti OR spolotane:ab,ti OR sterolone:ab,ti OR supercorti*ol:ab,ti OR taracortelone:ab,ti OR wysolone:ab,ti 
74 ‘pomalidomide’/de 
75 pomalidomide:ab,ti OR imnovid:ab,ti OR pomalyst:ab,ti OR 'cc-4047':ab,ti OR 'cc 4047':ab,ti OR cc4047:ab,ti  
76 ‘panobinostat’/de 
77 panobinostat:ab,ti OR farydak:ab,ti OR ‘lbh-589’:ab,ti OR ‘lbh589’:ab,ti OR ‘lbh 589’:ab,ti 
78 ‘carfilzomib’/de 
79 carfilzomib:ab,ti OR kyprolis:ab,ti OR ‘pr-171’:ab,ti  OR ‘pr171’:ab,ti OR ‘pr 171’:ab,ti 
80 ‘daratumumab’/de 
81 daratumumab:ab,ti OR darzalex:ab,ti 
82 `ixazomib’/de 
83 ixazomib:ab,ti OR ninlaro:ab,ti OR mln9708:ab,ti OR ‘mln 9708’:ab,ti OR ‘mln-9708’:ab,ti 
84 ‘elotuzumab’/de 
85 elotuzumab:ab,ti OR empliciti:ab,ti OR HuLuc63:ab,ti OR BMS-901608:ab,ti 
86 #50 OR #51 OR #52 OR #53 OR #54 OR #55 OR #56 OR #57 OR #58 OR #59 OR #60 OR #61 OR #62 OR #63 OR 
#64 OR #65 OR #66 OR #67 OR #68 OR #69 OR #70 OR #71 OR #72 OR #73 OR #74 OR #75 OR #76 OR #77 OR 
#78 OR #79 OR #80 OR #81 OR #82 OR #83 OR #84 OR #85 
87 #44 AND #49 AND #86 
88 #44 AND #49 AND #86 AND [1-1-2013]/sd NOT [31-12-2015]/sd 
  
1.2 Cochrane 
Database name  Cochrane 
Search interface http://www.thecochranelibrary.com/view/0/index.html 
Date of search   5 March 2016 
Time segment   2010 to 2016 
Search filter  Controlled clinical trials 
 
Table Cochrane search strategy 
# Search term 
1 MeSH descriptor: [Multiple Myeloma] explode all trees  
2 myeloma* 
3 proteasome inhibitor 
4 bortezomib  
5 (velcade OR ps341 OR "ps-341" OR (ps NEAR/1 341)) 
6 lenalidomide 
7 
revimid OR revlimid OR "cc 5013" OR cc5013 OR "cdc 501" OR "cdc 5013" OR cdc501 OR cdc5013 OR "enmd 0997" OR 
enmd0997 OR "imid 3" OR imid3  
8 thalidomide 
9 
thalidomid OR thalimodide OR thalomid OR contergan OR distaval OR isomin OR "k-17" OR kedavon OR kevadon OR 
neurosedin OR neurosedyne OR "nsc 66847" OR sedalis OR "shin naito" OR softenon OR synovir OR talimol OR talizer OR 
telagan OR telargan 
10 bendamustine 
11 "cimet 3393" OR cytostasan OR cytostasane OR "imet 3393" OR ribomustin OR treanda  
12 MeSH descriptor: [Dexamethasone] this term only 
13 MeSH descriptor: [Thalidomide] this term only 
14 MeSH descriptor: [Melphalan] this term only 
15 MeSH descriptor: [Vincristine] this term only 
16 MeSH descriptor: [Cyclophosphamide] this term only 
17 MeSH descriptor: [Doxorubicin] this term only 
18 MeSH descriptor: [Carmustine] this term only 
19 MeSH descriptor: [Prednisone] this term only 
20 MeSH descriptor: [Prednisolone] this term only 
21 
('aeroseb dex' OR aflucoson* OR anaflogistico OR arcodexan* OR azium OR calonat OR cebedex OR colofoam OR 
cortidron* OR cortisumman OR dacortin* OR dalalone OR decacortin OR decadeltoson* OR decadion OR decadr*n* OR 
decaesadril OR decamethasone OR decasone OR decaspray OR decasterolone OR decilone OR decofluor OR dectancyl OR 
dekacort OR delladec OR deltafluoren OR deltafluorene OR dergramin OR deronil OR desacort OR desacortone OR desadrene 
OR desalark OR desameton* OR 'dexa cortisyl' OR 'dexa dabrosan' OR 'dexa korti' OR 'dexa scherosan' OR 'dexa scherozon' 
OR 'dexa scherozone' OR dexachel OR dexacort* OR dexadabroson OR dexadecadrol OR dexadrol OR dexagen OR 
dexahelvacort OR dexakorti OR dexalocal OR dexamecortin OR dexameson* OR dexametason* OR dexameth OR 
dexametha*on* OR dexamethonium OR dexan OR dexane OR dexapot OR dexaschero*on* OR dexason* OR dexinoral OR 
dexionil OR dexone OR dextelan OR dezone OR doxamethasone OR esacortene OR exadion* OR firmalone OR fluormone 
OR fluorocort OR fluorodelta OR fortecortin OR gammacorten* OR grosodexon* OR hexadecad*ol OR hexadiol OR hexadrol 
OR isnacort OR isoptodex OR isoptomaxidex OR 'lokalison f' OR luxazone OR marvidione OR maxidex OR mediamethasone 
OR megacortin OR mephameson* OR metasolon* OR methazonion* OR millicorten OR millicortenol OR 'mk 125' OR 
mk125 OR nisomethasona OR novocort OR 'nsc 34521' OR nsc34521 OR opticorten OR opticortinol OR oradex*n* OR 
# Search term 
orgadrone OR policort OR posurdex OR prodexona OR prodexone OR sanamethasone OR spoloven OR triamcimetil OR 
visumethazone):ti,ab,kw 
22 
(melph*lan OR alkeran OR 'cb 3025' OR cb3025 OR 'levo sarcolysin' OR levofalan OR melfalan OR melphalon OR 'nsc 8806' 
OR nsc8806 OR 'phenylalanine 2037' OR 'phenylalanine mustard'):ti,ab,kw  
23 (vincristine OR vincristin OR 'l 37231' OR l37231 OR 'vin cristine' OR vincrisul):ti,ab,kw  
24 
(cyclophosphamide OR 'b 518' OR b518 OR carloxan OR clafen OR cycloblastin* OR 'cyclofos amide' OR cyclofosfamid* 
OR cyclophosphamid* OR cyclophosphan* OR cyclostin OR cycloxan OR cyphos OR cytophosphan* OR cytoxan OR 
'endocyclo phosphate' OR end*xan* OR genoxal OR 'mitoxan neosan' OR neosar OR noristan OR 'nsc 26271' OR 'nsc 2671' 
OR procytox OR procytoxide OR se*doxan):ti,ab,kw 
25 
(doxorubicin OR adriablastin OR adriablastin* AND adriacin OR adriamicin* OR adriblastin* OR caelyx OR doxil OR 
doxorubicine OR 'fi 106' OR fi106 OR lipodox OR myocet OR 'nsc 123127' OR nsc123127 OR rastocin OR resmycin OR 'rp 
25253' OR rp25253 OR rubex OR sarcodoxome OR 'tlc d 99'):ti,ab,kw  
26 (carmustine OR bcnu OR bicnu OR carmubis OR carmubris OR carmustin OR gliadel OR nitrumon OR 'nsc 409962'):ti,ab,kw  
27 
(prednisone OR ancortone OR biocortone OR colisone OR cortidelt OR 'de cortisyl' OR decortancyl OR de*ortin* OR 
dehydrocortisone OR delitisone OR deltacort*n* OR deltacortisone OR deltasone OR deltra OR 'di-adreson' OR diadreson OR 
en*orton* OR hostacortin OR insone OR meprison OR metacortandracin OR meticorten OR meticortine OR 'nsc 10023' OR 
nsc10023 OR orasone* OR paracort OR precort OR precortal OR prednisone* OR pronizone OR rectodelt OR ultracorten OR 
urtilone):ti,ab,kw 
28 
(prednisolone OR antisolon* OR aprednislon* OR benisolon* OR berisolon* OR caberdelta OR 'co hydeltra' OR codelcortone 
OR cortadelton* OR cortelinter OR cortisolone OR dacortin OR decortril OR dehydrocortex OR dehydrocortisol* OR 
dehydrohydrocortison* OR delcortol OR deltacortef OR deltacortenolo OR deltacortil OR deltacortoil OR deltaderm OR 
deltaglycortril OR deltahycortol OR deltahydrocortison* OR deltaophticor OR deltasolone OR deltastab OR deltidrosol OR 
deltisilone OR deltisolon* OR deltolasson* OR deltoson* OR dicortol OR domucortone OR encort*lon* OR glistelone OR 
hostacortin OR hydeltra OR hydeltrone OR hydrelta OR hydrocortancyl OR hydrocortidelt OR hydrodeltalone OR 
hydrodeltisone OR hydroretrocortin* OR inflanefran OR insolone OR keteocort OR leocortol OR mediasolone OR 
meprisolon* OR metacortalon* OR metacortandralon* OR metacortelone OR meticortelone OR metiderm OR morlone OR 
mydrapred OR nisolon OR nisolone OR 'nsc 9120' OR nsc9120 OR panafcortolone OR panafort OR paracortol OR phlogex 
OR precortalon OR precortancyl OR precortisyl OR predartrin* OR prednedome OR prednelan OR prednicoelin OR prednicort 
OR prednicortelone OR prednifor OR predniment OR predniretard OR prednis OR prednivet OR prednorsolon* OR predonine 
OR predorgasolon* OR prelone OR prenolone OR prezolon OR scherisolon OR serilone OR solone OR solupren* OR spiricort 
OR spolotane OR sterolone OR supercorti*ol OR taracortelone OR wysolone):ti,ab,kw  
29 pomalidomide 
30 (imnovid OR pomalyst OR “cc-4047” OR “cc 4047” OR cc4047):ti,ab,kw  
31 panobinostat 
32 (farydak OR “lbh-589” OR “lbh589” OR “lbh 589”):ti,ab,kw 
33 carfilzomib 




38 (ninlaro OR mln9708 OR “mln 9708” OR “mln-9708” OR (proteasome NEXT/1 inhibit*)):ti,ab,kw 
39 elotuzumab 
40 (empliciti OR HuLuc63 OR BMS-901608):ti,ab,kw 
41 
(#3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR 
#19 OR #20 OR #21 OR #22 OR #23 OR #24 OR #25 OR #26 OR #27 OR #28 OR #29 OR #30 OR #31 OR #32 OR #33 OR 
#34 OR #35 OR #36 OR #37 OR #38 OR #39 OR #40)  
42 (#1 OR #2) 
31 (#41 AND #42) 
# Search term 
32 (#41 AND #42), Publication Year from 2013 to 2015 in Trials 
  
1.3 MEDLINE® In-Process 
Database name  MEDLINE® In-Process 
Search interface http://www.ncbi.nlm.nih.gov/pubmed/ 
Date of search   5 March 2016 
Time segment   None 
Search filter  Limited to In-Process citations 
 
Table MEDLINE® In-Process search 
#  Search term 
1 Search myeloma* 
2 Search Bortezomib 
3 Search Lenalidomide 
4 Search Thalidomide 
5 Search Bendamustine 
6 Search Dexamethasone 
7 Search Melphalan 
8 Search Vincristine 
9 Search Cyclophosphamide 
10 Search Doxorubicin 
11 Search Carmustine 
12 Search Prednisone 
13 Search Prednisolone 
14 Search velcade 
15 Search proteasome inhibitor 
16 Search revlimid 
17 Search treanda 
18 Search cytoxan 
19 Search endoxan 
20 Search neosar 
21 Search adriamycin 
22 Search caelyx 
23 Search doxil 
24 Search gliadel 
25 Search ancortone 
26 Search encortone 
27 Search pomalidomide 
28 Search imnovid 
#  Search term 
29 Search pomalyst 
30 Search panobinostat 
31 Search farydak 
32 Search carfilzomib 
33 Search kyprolis 
34 Search daratumumab 
35 Search darzalex 
36 Search ixazomib 
37 Search ninlaro 
38 Search elotuzumab 
39 Search empliciti 
40 
Search (((((((((((((((((((((((((((((((((((((#2) OR #3) OR #4) OR #5) OR #6) OR #7) OR #8) OR #9) OR #10) OR #11) OR #12) 
OR #13) OR #14) OR #15) OR #16) OR #17) OR #18) OR #19) OR #20) OR #21) OR #22) OR #23) OR #24) OR #25) OR 
#26) OR #27) OR #28) OR #29) OR #30) OR #31) OR #32) OR #33) OR #34) OR #35) OR #36) OR #37) OR #38) OR #39 
41 Search (#1) AND #40 
42 Search #41 AND inprocess[sb] 
 
1.4 Trials in progress 
Database name  Clinicaltrials.gov 
Search interface http://www.clinicaltrial.gov 
Date of search   21 June 2016 
Time segment   None 
Search filter  Limited to randomised, interventional studies in multiple myeloma 
 
Table Search strategy for trials in progress 
#  Search term 
1 Search term: random* 
Limited to condition: multiple myeloma 











Age: adults aged ≥18 years 
Gender: any 
Race: any 
Stage of disease: any 
Line of therapy:  
Any (for chemotherapy setting) 
First-line (for transplant setting) 
Type of therapy 
Any (for chemotherapy setting) 
Pre-transplant induction therapy (for transplant setting) 
Post-transplant consolidation or maintenance therapy (for transplant setting) 
 
Interventions:  
























1999 onwards for database searches 




RCTs with any blinding status 
Non-randomised controlled clinical trials 




Phase I studies 
Pharmacokinetic studies 
No subgroup analysis for MM 
Conference abstracts published prior to 2008  
Conference abstracts (other than those searched for this review) published after 2008 (retrieved from the 
literature database) 
Transplant setting  
Preparative regimen 
Conditioning regimen 
Mobilisation regimen  
Appendix 3.1 PRISMA checklist  
Section/topic  # Checklist item  
Reported 
on page #  
TITLE   
Title  1 Identify the report as a systematic review, meta-analysis, or both.  1 
ABSTRACT   
Structured summary  2 Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, 
participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and 
implications of key findings; systematic review registration number.  
3 
INTRODUCTION   
Rationale  3 Describe the rationale for the review in the context of what is already known.  6  
Objectives  4 Provide an explicit statement of questions being addressed with reference to participants, interventions, 
comparisons, outcomes, and study design (PICOS).  
6 
METHODS   
Protocol and registration  5 Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide 
registration information including registration number.  
6 
Eligibility criteria  6 Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, 
language, publication status) used as criteria for eligibility, giving rationale.  
6 
Information sources  7 Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify 
additional studies) in the search and date last searched.  
6 





Study selection  9 State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, 




Data collection process  10 Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes 
for obtaining and confirming data from investigators.  
7 
Data items  11 List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and 
simplifications made.  
7 
Risk of bias in individual 
studies  
12 Describe methods used for assessing risk of bias of individual studies (including specification of whether this was 
done at the study or outcome level), and how this information is to be used in any data synthesis.  
Appendix 
3 
Summary measures  13 State the principal summary measures (e.g., risk ratio, difference in means).  7 
Synthesis of results  14 Describe the methods of handling data and combining results of studies, if done, including measures of consistency 
(e.g., I2) for each meta-analysis.  
8 
 
Page 1 of 2  
Section/topic  # Checklist item  
Reported 
on page #  
Risk of bias across studies  15 Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective 
reporting within studies).  
Appendix 
3 
Additional analyses  16 Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating 
which were pre-specified.  
8 
RESULTS   
Study selection  17 Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at 
each stage, ideally with a flow diagram.  
8-9 
(Figure 1) 
Study characteristics  18 For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and 
provide the citations.  
9 (Table 
1) 
Risk of bias within studies  19 Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).  Appendix 
3 
Results of individual studies  20 For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each 
intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.  
9 (Table 
1) 
Synthesis of results  21 Present results of each meta-analysis done, including confidence intervals and measures of consistency.  10-11 
(Figure 3 
Risk of bias across studies  22 Present results of any assessment of risk of bias across studies (see Item 15).  Appendix 
3 
Additional analysis  23 Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).  11-12 
(Appendix 
5, 6, 7, 8) 
DISCUSSION   
Summary of evidence  24 Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to 
key groups (e.g., healthcare providers, users, and policy makers).  
12-16 
Limitations  25 Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of 
identified research, reporting bias).  
12-16 
Conclusions  26 Provide a general interpretation of the results in the context of other evidence, and implications for future research.  12-16 
FUNDING   
Funding  27 Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the 
systematic review.  
8 
 
From:  Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(7): 
e1000097. doi:10.1371/journal.pmed1000097  
For more information, visit: www.prisma-statement.org.  
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Facon 2006 Low risk Low risk High risk Low risk Low risk Unclear Unclear Unclear High risk 
Facon 2007 Low risk Unclear High risk Low risk Low risk High risk High risk Unclear High risk 
Morgan 2013 Low risk Unclear High risk Low risk Low risk Unclear Unclear Unclear Low risk 
Rajkumar 2008 Low risk Low risk Low risk Low risk Low risk Unclear Unclear Unclear Low risk 
Ludwig 2009 Low risk Low risk High risk Low risk Low risk Unclear Unclear Unclear Unclear 
Palumbo 2008 Low risk Low risk High risk Low risk Low risk High risk High risk Unclear High risk 
Hulin 2009 Low risk Unclear Low risk Low risk Low risk Low risk Low risk Unclear Low risk 
Waage 2010 Low risk Low risk Low risk Low risk Low risk Unclear Unclear Unclear Low risk 
Beksac 2010 Low risk Low risk High risk Low risk Low risk Unclear Unclear Unclear Low risk 
Wijermans 2010 Low risk Unclear High risk Low risk Low risk Unclear Unclear Unclear High risk 
Sacchi 2011 Low risk Low risk High risk Low risk Low risk Unclear Unclear Unclear Low risk 
Hungria 2016 Low risk Unclear High risk Low risk Low risk Low risk Low risk Unclear High risk 
San Miguel 2008 Low risk Unclear High risk Low risk Low risk Low risk Low risk Unclear Low risk 
Mateos 2014 Low risk Low risk High risk Low risk Low risk Low risk Low risk Unclear Low risk 
Niesvizky 2015 Low risk Low risk High risk Low risk Low risk Low risk Low risk Unclear Low risk 
Palumbo 2014 Low risk Unclear Unclear Low risk Low risk Low risk Low risk Unclear Low risk 
Zonder 2011 Low risk Unclear High risk Low risk Low risk Low risk Unclear Unclear High risk 
Benboubkher 2014 Low risk Low risk High risk Low risk Low risk Low risk Low risk Unclear Low risk 
Zweegman 2016 Low risk Low risk High risk Low risk Low risk Unclear Unclear Unclear Low risk 
Stewart 2015 Low risk Low risk High risk Low risk Low risk Low risk Low risk Unclear Low risk 
Magarotto 2016 Low risk Unclear High risk Low risk Low risk Unclear Unclear Unclear Low risk 
Palumbo 2012 Low risk Unclear Low risk Low risk Low risk Low risk Low risk Unclear Low risk 
Durie 2017 Low risk Low risk High risk Low risk Low risk Unclear Unclear Unclear High risk 
Mateos 2018 Low risk Low risk High risk Low risk Low risk Low risk Low risk Unclear Low risk 
   
Appendix 4 R script Netmeta 
#################################################################################################### 
##################################################################################################### 
# Network meta-analysis of newly diagnosed  not transplant eligble multiple myeloma treatments 
# using R-package netmeta 
# accompanying publication titled "Efficacy of first-line treatments for multiple myeloma patients not eligible for   
# stem cell transplantation - A Network Meta-analysis"  









# The Multiple Myeloma data. 
################################################################################################### 
 
# Data abstracted from phase III randomized controlled trials found in systematic literature review  
# with time period 01 January 1999 to 01 March 2016 
 
# Data is entered as contrast-level data to be used in the 'netmeta' package. 
 
# We stored this data into a data.frame called 'myeloma_data'. 
 
# myeloma_data had the columns: 
# TE (holding relative treatment effect estimates for pairs of treatments within studies, ie. log hazard ratio), 
# seTE (holding standard errors for the treatment effect estimates TE), 
# treat1.long (holding treatment names for the first of a pair of treatments),  
# treat2.long (holding treatment names for the second of a pair of treatments),  
# treat1 (holding abbreviated treatment names for the first of a pair of treatments),  
# treat2 (holding abbreviated treatment names for the second of a pair of treatments),  
# studlabel (holding study labels) 
 
# Load the data: 
myeloma_data = read.csv("data/TNEMM_NMA_data.csv") # Read data file; must be in curr. work. dir. 
 
###### Load required R packages ################################################################### 
 
# netmeta (version 0.9-7, built under R version 3.3.3) 
library("netmeta") 
 
###### Prepare data for package ################################################################### 
 
# Note: Data (myeloma_data) is imported as contrast-level. 
# Data is ready as loaded in. 
 
###### Choose and run model ####################################################################### 
 
net1 <- netmeta(TE, seTE, treat1, treat2, studlab, data=myeloma_data, sm="HR",  
                details.chkmultiarm=TRUE, comb.random=TRUE, reference.group="D",  
                tol.multiarm = 0.05) 
 




###### Assess the degree of heterogeneity and inconsistency ####################################### 
 








# A graphical tool for locating inconsistency in network meta-analyses. 
netheat(net1, random=TRUE) 
 
###### Report relative effect estimates ########################################################### 
# To produce summary of netmeta model 
summary(net1,ref="D",digits=2) 
 
# Rank treatments 
net1.rank<-netrank(net1, small.values = "good") 
 
# Forest plot 
forest.netmeta(net1, reference.group = "D", sortvar = -net1.rank$Pscore.random, digits.Pscore = 2,  
               leftcols="studlab", leftlabs="Treatment", rightcols=c("effect", "ci", "Pscore"),  
               rightlabs="P-Score", just.addcols="right" , xlab="HR progression-free survival", label.right="                 Favors `D`", 
               label.left="Favors other treatment             ", xlim=c(0.05,20)) 
 
forest.netmeta(net1, reference.group = "MPT/MPT-T", sortvar = -net1.rank$Pscore.random, digits.Pscore = 2,  
               leftcols="studlab", leftlabs="Treatment", rightcols=c("effect", "ci", "Pscore"),  
               rightlabs="P-Score", just.addcols="right" , xlab="HR progression-free survival", label.right="               Favors 
`MPT/MPT-T`", 
               label.left="Favors other treatment             ", xlim=c(0.1,10)) 
 
 




# SCENARIO ANALYSES 
# 
# #1: differentiate between MPT and MPT-T (thal maintenance split) [MPT-T: GIMEMA, HOVON49, TMSG, NMSG, 
HOVON87, E1A06] 
# #2: Weisel replication (VISTA, IFM 01/01, IFM 99/66, Sacchi and FIRST) 
# #3: Fixed effect model 
################################################################################################### 
 
###### SA1: Different grouping for Thal maintenance (MPT-T and MPT) 
 # Load the data: 
mmData1 = read.csv("data/TNEMM_NMA_data-ThalMaintSA.csv")  
 
# Model 
net1.ThalSA <- netmeta(TE, seTE, treat1, treat2, studlab, data=mmData1, sm="HR",  
                       details.chkmultiarm=TRUE, comb.random=TRUE, reference.group="D",  
                       tol.multiarm = 0.05) 
 
# Rank treatments 
net1.ThalSA.rank<-netrank(net1.ThalSA, small.values = "good") 
 
# Forest plot 
forest.netmeta(net1.ThalSA, reference.group = "D", sortvar = -net1.ThalSA.rank$Pscore.random, digits.Pscore = 2,  
               leftcols="studlab", leftlabs="Treatment", rightcols=c("effect", "ci", "Pscore"),  
               rightlabs="P-Score", just.addcols="right" , xlab="HR progression-free survival", label.right="                 Favors D", 
               label.left="Favors other treatment             ", xlim=c(0.05,20)) 
 
###### SA2: Weisel replication (VISTA, IFM 01/01, IFM 99/66, Sacchi and FIRST) 
 
# Load the data: 
mmData2 = read.csv("data/TNEMM_NMA_data-Weisel.csv")  
 
# Fixed effect model 
net1.Weis <- netmeta(TE, seTE, treat1, treat2, studlab, data=mmData2, sm="HR",  
                      details.chkmultiarm=TRUE, comb.random=TRUE, reference.group="Rd")  
 
# Rank treatments 
net1.Weis.rank<-netrank(net1.Weis, small.values = "good") 
 
# Forest plot 
forest(net1.Weis, ref="Rd", sortvar = -net1.Weis.rank$Pscore.random , digits.Pscore = 2,  
       leftcols="studlab", leftlabs="Treatment", rightcols=c("effect", "ci", "Pscore"),  
       rightlabs="P-Score", just.addcols="right" , xlab="HR progression-free survival", label.right="               Favors RD", 
       label.left="Favors other treatment             ", xlim=c(0.2,5) ) 
 
###### SA3: Fixed effect model 
net1.FE <- netmeta(TE, seTE, treat1, treat2, studlab, data=myeloma_data, sm="HR",  
                   details.chkmultiarm=TRUE, comb.random=FALSE, reference.group="D",  
                   tol.multiarm = 0.05) 
 
net1.FE.rank<-netrank(net1.FE, small.values = "good") 
 
forest(net1.FE, ref="D", sortvar = -net1.FE.rank$Pscore.random, digits.Pscore = 2,  
       leftcols="studlab", leftlabs="Treatment", rightcols=c("effect", "ci", "Pscore"),  
       rightlabs="P-Score", just.addcols="right" , xlab="HR progression-free survival", label.right="                 Favors D", 
       label.left="Favors other treatment             ", xlim=c(0.05,20) ) 
################################################################################# 






# #1: main analysis  
# #2: scenario analysis #1 Different grouping for Thal maintenance (MPT-T and MPT)  
# #3: scenario analysis #2 Replicating Weisel’s NMA 
# #4: scenario analysis #4 Fixed effect model 
################################################################################# 
 
###### #1: data for main analysis [[file name: TNEMM_NMA_data.csv]] 
TE seTE treat1 treat2 studlab 
-0.70694 0.132986 TD D Rajkumar2008 
0.26266 0.160183 TD MP Ludwig2009 
-0.47235 0.133484 MPT/MPT-T MP Palumbo2008 
-0.48749 0.147472 MPT/MPT-T MP IFM-01/01 
-0.11723 0.122169 MPT/MPT-T MP NMSG 
-0.35525 0.261358 MPT/MPT-T MP TMSG 
-0.23902 0.12195 MPT/MPT-T MP HOVON49 
-0.40103 0.289061 MPT/MPT-T MP Sacchi2011 
-0.22754 0.136104 VMP VTP GEM2005 
-0.21647 0.078876 CTD(a) MP MRC-MIX 
-0.58344 0.176245 VMP MP VISTA 
-0.54876 0.10524 VMPT-VT VMP GIMEMA0305 
-0.58867 0.180076 Rd D S0232 
-0.14464 0.093809 MPR-R MPT/MPT-T HOVON87 
-0.33927 0.117128 VRd Rd S0777 
-0.18005 0.135835 MPT/MPT-T MPR-R E1A06 
-0.69918 0.136942 DaraVMP VMP ALCYONE 
-0.67856 0.13421 MPT/MPT-T MP IFM-99/06 
-0.11964 0.313441 MPT/MPT-T CTD Hungria2016 
0.108844 0.144491 VD VMP UPFRONT 
-0.2169 0.12426 MPR-R Rd EMN01 
-0.70552 0.168967 MPR-R MPR MM-015 
0.328408 0.084639 MPT/MPT-T Rd FIRST 
-0.28476 0.098832 MP D Facon2006 
-0.14518 0.122699 M100 MP IFM-99/06 
0.101185 0.375549 TD CTD Hungria2016 
-0.11245 0.154629 VTD VMP UPFRONT 
0.004314 0.0588 CPR Rd EMN01 
0.173842 0.11798 MP MPR MM-015 
0.354638 0.079689 Rd18 Rd FIRST 
-0.41903 0.107257 MD D Facon2006 
-0.53472 0.146053 MPT/MPT-T M100 IFM-99/06 
-0.31326 0.395568 MPT/MPT-T TD Hungria2016 
0.11289 0.152666 VD VTD UPFRONT 
-0.22676 0.123291 MPR-R CPR EMN01 
-0.91864 0.156192 MPR-R MP MM-015 
-0.03289 0.07624 MPT/MPT-T Rd18 FIRST 
0.139955 0.106084 MP MD Facon2006 
-0.08317 0.094656 DI D Facon2006 
0.231945 0.099595 DI MP Facon2006 
0.370823 0.10788 DI MD Facon2006 
 
##### #2: data for scenario analysis #1 with thalidomide maintenance split [[file name: 
TNEMM_NMA_data-ThalMaintSA.csv]] 
TE seTE treat1 treat2 studlab 
-0.70694 0.132986 TD D Rajkumar2008 
0.26266 0.160183 TD MP Ludwig2009 
-0.47235 0.133484 MPT-T MP Palumbo2008 
-0.48749 0.147472 MPT MP IFM-01/01 
-0.11723 0.122169 MPT-T MP NMSG 
-0.35525 0.261358 MPT-T MP TMSG 
-0.23902 0.12195 MPT-T MP HOVON49 
-0.40103 0.289061 MPT MP Sacchi2011 
-0.22754 0.136104 VMP VTP GEM2005 
-0.21647 0.078876 CTD(a) MP MRC-MIX 
-0.58344 0.176245 VMP MP VISTA 
-0.54876 0.10524 VMPT-VT VMP GIMEMA0305 
-0.58867 0.180076 Rd D S0232 
-0.14464 0.093809 MPR-R MPT-T HOVON87 
-0.33927 0.117128 VRd Rd S0777 
-0.18005 0.135835 MPT-T MPR-R E1A06 
-0.69918 0.136942 DaraVMP VMP ALCYONE 
-0.67856 0.13421 MPT MP IFM-99/06 
-0.11964 0.313441 MPT CTD Hungria2016 
0.108844 0.144491 VD VMP UPFRONT 
-0.2169 0.12426 MPR-R Rd EMN01 
-0.70552 0.168967 MPR-R MPR MM-015 
0.328408 0.084639 MPT Rd FIRST 
-0.28476 0.098832 MP D Facon2006 
-0.14518 0.122699 M100 MP IFM-99/06 
0.101185 0.375549 TD CTD Hungria2016 
-0.11245 0.154629 VTD VMP UPFRONT 
0.004314 0.0588 CPR Rd EMN01 
0.173842 0.11798 MP MPR MM-015 
0.354638 0.079689 Rd18 Rd FIRST 
-0.41903 0.107257 MD D Facon2006 
-0.53472 0.146053 MPT M100 IFM-99/06 
-0.31326 0.395568 MPT TD Hungria2016 
0.11289 0.152666 VD VTD UPFRONT 
-0.22676 0.123291 MPR-R CPR EMN01 
-0.91864 0.156192 MPR-R MP MM-015 
-0.03289 0.07624 MPT Rd18 FIRST 
0.139955 0.106084 MP MD Facon2006 
-0.08317 0.094656 DI D Facon2006 
0.231945 0.099595 DI MP Facon2006 
0.370823 0.10788 DI MD Facon2006 
 
##### #3: data for scenario analysis #2 Replicating Weisel’s NMA [[file name: 
TNEMM_NMA_data-Weisel.csv]] 
TE seTE treat1 treat2 studlab 
-0.48749 0.147472 MPT MP IFM-01/01 
-0.40103 0.289061 MPT MP Sacchi2011 
-0.58344 0.176245 VMP MP VISTA 
-0.67856 0.13421 MPT MP IFM-99/06 
0.328408 0.084639 MPT Rd FIRST 
 
















































CPR:CTD 0 0 0.8332 . 0.8332 . . . 
CPR:CTD(a) 0 0 0.8152 . 0.8152 . . . 
CPR:D 0 0 0.4577 . 0.4577 . . . 
CPR:DaraVMP 0 0 2.3674 . 2.3674 . . . 
CPR:DI 0 0 0.5067 . 0.5067 . . . 
CPR:M100 0 0 0.6693 . 0.6693 . . . 
CPR:MD 0 0 0.7282 . 0.7282 . . . 
CPR:MP 0 0 0.6565 . 0.6565 . . . 
CPR:MPR 0 0 0.6935 . 0.6935 . . . 
CPR:MPR-R 1 0.82 1.1777 1.2545 0.8818 1.4226 0.58 0.5629 
CPR:MPT 0 0 0.9823 . 0.9823 . . . 
CPR:Rd 1 0.89 1.0498 1.0043 1.5196 0.6609 -0.58 0.5629 
CPR:Rd18 0 0 0.8376 . 0.8376 . . . 
CPR:TD 0 0 0.7034 . 0.7034 . . . 
CPR:VD 0 0 1.0922 . 1.0922 . . . 
CPR:VMP 0 0 1.1766 . 1.1766 . . . 
CPR:VMPT-VT 0 0 2.0368 . 2.0368 . . . 
CPR:VRd 0 0 1.4738 . 1.4738 . . . 
CPR:VTD 0 0 1.2684 . 1.2684 . . . 
CPR:VTP 0 0 0.9371 . 0.9371 . . . 
CTD(a):CTD 0 0 1.0222 . 1.0222 . . . 
D:CTD 0 0 1.8204 . 1.8204 . . . 
DaraVMP:CTD 0 0 0.352 . 0.352 . . . 
DI:CTD 0 0 1.6445 . 1.6445 . . . 
M100:CTD 0 0 1.245 . 1.245 . . . 
MD:CTD 0 0 1.1442 . 1.1442 . . . 
MP:CTD 0 0 1.2692 . 1.2692 . . . 
MPR:CTD 0 0 1.2015 . 1.2015 . . . 
MPR-R:CTD 0 0 0.7075 . 0.7075 . . . 
MPT:CTD 1 0.83 0.8483 0.8872 0.686 1.2933 0.28 0.781 
Rd:CTD 0 0 0.7937 . 0.7937 . . . 
Rd18:CTD 0 0 0.9948 . 0.9948 . . . 












































VD:CTD 0 0 0.7629 . 0.7629 . . . 
VMP:CTD 0 0 0.7082 . 0.7082 . . . 
VMPT-VT:CTD 0 0 0.4091 . 0.4091 . . . 
VRd:CTD 0 0 0.5654 . 0.5654 . . . 
VTD:CTD 0 0 0.6569 . 0.6569 . . . 
VTP:CTD 0 0 0.8891 . 0.8891 . . . 
D:CTD(a) 0 0 1.7809 . 1.7809 . . . 
DaraVMP:CTD(a) 0 0 0.3443 . 0.3443 . . . 
DI:CTD(a) 0 0 1.6088 . 1.6088 . . . 
M100:CTD(a) 0 0 1.218 . 1.218 . . . 
MD:CTD(a) 0 0 1.1194 . 1.1194 . . . 
MP:CTD(a) 1 1 1.2417 1.2417 . . . . 
MPR:CTD(a) 0 0 1.1754 . 1.1754 . . . 
MPR-R:CTD(a) 0 0 0.6922 . 0.6922 . . . 
MPT:CTD(a) 0 0 0.8298 . 0.8298 . . . 
Rd:CTD(a) 0 0 0.7765 . 0.7765 . . . 
Rd18:CTD(a) 0 0 0.9732 . 0.9732 . . . 
TD:CTD(a) 0 0 1.1589 . 1.1589 . . . 
VD:CTD(a) 0 0 0.7464 . 0.7464 . . . 
VMP:CTD(a) 0 0 0.6928 . 0.6928 . . . 
VMPT-VT:CTD(a) 0 0 0.4002 . 0.4002 . . . 
VRd:CTD(a) 0 0 0.5531 . 0.5531 . . . 
VTD:CTD(a) 0 0 0.6427 . 0.6427 . . . 
VTP:CTD(a) 0 0 0.8699 . 0.8699 . . . 
DaraVMP:D 0 0 0.1933 . 0.1933 . . . 
DI:D 1 0.88 0.9034 0.9202 0.7885 1.167 0.22 0.8278 
M100:D 0 0 0.6839 . 0.6839 . . . 
MD:D 1 0.88 0.6285 0.6577 0.4499 1.4618 0.52 0.6007 
MP:D 1 0.51 0.6972 0.7522 0.6437 1.1686 0.44 0.66 
MPR:D 0 0 0.66 . 0.66 . . . 
MPR-R:D 0 0 0.3887 . 0.3887 . . . 
MPT:D 0 0 0.466 . 0.466 . . . 











































Rd18:D 0 0 0.5465 . 0.5465 . . . 
TD:D 1 0.58 0.6508 0.4932 0.9593 0.5141 -1.64 0.102 
VD:D 0 0 0.4191 . 0.4191 . . . 
VMP:D 0 0 0.389 . 0.389 . . . 
VMPT-VT:D 0 0 0.2247 . 0.2247 . . . 
VRd:D 0 0 0.3106 . 0.3106 . . . 
VTD:D 0 0 0.3609 . 0.3609 . . . 
VTP:D 0 0 0.4884 . 0.4884 . . . 
DI:DaraVMP 0 0 4.6722 . 4.6722 . . . 
M100:DaraVMP 0 0 3.5373 . 3.5373 . . . 
MD:DaraVMP 0 0 3.2508 . 3.2508 . . . 
MP:DaraVMP 0 0 3.6061 . 3.6061 . . . 
MPR:DaraVMP 0 0 3.4136 . 3.4136 . . . 
MPR-R:DaraVMP 0 0 2.0101 . 2.0101 . . . 
MPT:DaraVMP 0 0 2.41 . 2.41 . . . 
Rd:DaraVMP 0 0 2.2551 . 2.2551 . . . 
Rd18:DaraVMP 0 0 2.8264 . 2.8264 . . . 
TD:DaraVMP 0 0 3.3658 . 3.3658 . . . 
VD:DaraVMP 0 0 2.1676 . 2.1676 . . . 
VMP:DaraVMP 1 1 2.0121 2.0121 . . . . 
VMPT-VT:DaraVMP 0 0 1.1623 . 1.1623 . . . 
VRd:DaraVMP 0 0 1.6063 . 1.6063 . . . 
VTD:DaraVMP 0 0 1.8665 . 1.8665 . . . 
VTP:DaraVMP 0 0 2.5262 . 2.5262 . . . 
M100:DI 0 0 0.7571 . 0.7571 . . . 
MD:DI 1 1 0.6958 0.6902 . . . . 
MP:DI 1 0.87 0.7718 0.793 0.6389 1.2411 0.31 0.7573 
MPR:DI 0 0 0.7306 . 0.7306 . . . 
MPR-R:DI 0 0 0.4302 . 0.4302 . . . 
MPT:DI 0 0 0.5158 . 0.5158 . . . 
Rd:DI 0 0 0.4827 . 0.4827 . . . 
Rd18:DI 0 0 0.6049 . 0.6049 . . . 
TD:DI 0 0 0.7204 . 0.7204 . . . 
VD:DI 0 0 0.4639 . 0.4639 . . . 
VMP:DI 0 0 0.4307 . 0.4307 . . . 












































VRd:DI 0 0 0.3438 . 0.3438 . . . 
VTD:DI 0 0 0.3995 . 0.3995 . . . 
VTP:DI 0 0 0.5407 . 0.5407 . . . 
M100:MD 0 0 1.0881 . 1.0881 . . . 
M100:MP 1 0.81 0.9809 0.8649 1.6979 0.5094 -1.13 0.258 
M100:MPR 0 0 1.0362 . 1.0362 . . . 
M100:MPR-R 0 0 1.7597 . 1.7597 . . . 
M100:MPT 1 0.75 1.4678 1.707 0.9222 1.8511 1.13 0.258 
M100:Rd 0 0 1.5686 . 1.5686 . . . 
M100:Rd18 0 0 1.2515 . 1.2515 . . . 
M100:TD 0 0 1.051 . 1.051 . . . 
M100:VD 0 0 1.6319 . 1.6319 . . . 
M100:VMP 0 0 1.758 . 1.758 . . . 
M100:VMPT-VT 0 0 3.0433 . 3.0433 . . . 
M100:VRd 0 0 2.2022 . 2.2022 . . . 
M100:VTD 0 0 1.8952 . 1.8952 . . . 
M100:VTP 0 0 1.4002 . 1.4002 . . . 
MP:MD 1 0.88 1.1093 1.1502 0.8458 1.3599 0.42 0.6731 
MPR:MD 0 0 1.0501 . 1.0501 . . . 
MPR-R:MD 0 0 0.6183 . 0.6183 . . . 
MPT:MD 0 0 0.7414 . 0.7414 . . . 
Rd:MD 0 0 0.6937 . 0.6937 . . . 
Rd18:MD 0 0 0.8694 . 0.8694 . . . 
TD:MD 0 0 1.0353 . 1.0353 . . . 
VD:MD 0 0 0.6668 . 0.6668 . . . 
VMP:MD 0 0 0.619 . 0.619 . . . 
VMPT-VT:MD 0 0 0.3575 . 0.3575 . . . 
VRd:MD 0 0 0.4941 . 0.4941 . . . 
VTD:MD 0 0 0.5741 . 0.5741 . . . 
VTP:MD 0 0 0.7771 . 0.7771 . . . 
MP:MPR 1 0.87 1.0564 1.1899 0.4788 2.4852 1.29 0.1976 
MP:MPR-R 1 0.31 1.7939 2.5059 1.546 1.6208 1.46 0.1443 
MP:MPT 7 0.83 1.4963 1.4783 1.5895 0.93 -0.28 0.7806 
MP:Rd 0 0 1.5991 . 1.5991 . . . 
MP:Rd18 0 0 1.2759 . 1.2759 . . . 
MP:TD 1 0.49 1.0714 0.769 1.4766 0.5208 -1.68 0.0937 
MP:VD 0 0 1.6636 . 1.6636 . . . 













































MP:VMPT-VT 0 0 3.1025 . 3.1025 . . . 
MP:VRd 0 0 2.245 . 2.245 . . . 
MP:VTD 0 0 1.932 . 1.932 . . . 
MP:VTP 0 0 1.4275 . 1.4275 . . . 
MPR:MPR-R 1 0.77 1.6982 2.0249 0.9531 2.1245 1.29 0.1976 
MPR:MPT 0 0 1.4164 . 1.4164 . . . 
MPR:Rd 0 0 1.5137 . 1.5137 . . . 
MPR:Rd18 0 0 1.2077 . 1.2077 . . . 
MPR:TD 0 0 1.0142 . 1.0142 . . . 
MPR:VD 0 0 1.5748 . 1.5748 . . . 
MPR:VMP 0 0 1.6965 . 1.6965 . . . 
MPR:VMPT-VT 0 0 2.9368 . 2.9368 . . . 
MPR:VRd 0 0 2.1251 . 2.1251 . . . 
MPR:VTD 0 0 1.8289 . 1.8289 . . . 
MPR:VTP 0 0 1.3513 . 1.3513 . . . 
MPR-R:MPT 2 0.6 0.8341 1.0057 0.627 1.6039 1.65 0.0981 
MPR-R:Rd 1 0.48 0.8914 0.805 0.9806 0.821 -0.55 0.5832 
MPR-R:Rd18 0 0 0.7112 . 0.7112 . . . 
MPR-R:TD 0 0 0.5972 . 0.5972 . . . 
MPR-R:VD 0 0 0.9273 . 0.9273 . . . 
MPR-R:VMP 0 0 0.999 . 0.999 . . . 
MPR-R:VMPT-VT 0 0 1.7294 . 1.7294 . . . 
MPR-R:VRd 0 0 1.2514 . 1.2514 . . . 
MPR-R:VTD 0 0 1.077 . 1.077 . . . 
MPR-R:VTP 0 0 0.7957 . 0.7957 . . . 
MPT:Rd 1 0.48 1.0687 1.3888 0.8351 1.6629 1.51 0.1313 
MPT:Rd18 1 0.87 0.8527 0.9676 0.3641 2.6575 1.47 0.1414 
MPT:TD 1 0.2 0.716 0.7311 0.7123 1.0264 0.05 0.9594 
MPT:VD 0 0 1.1118 . 1.1118 . . . 
MPT:VMP 0 0 1.1978 . 1.1978 . . . 
MPT:VMPT-VT 0 0 2.0734 . 2.0734 . . . 
MPT:VRd 0 0 1.5004 . 1.5004 . . . 
MPT:VTD 0 0 1.2912 . 1.2912 . . . 












































Rd:Rd18 1 0.87 0.7979 0.7014 1.8477 0.3796 -1.47 0.1414 
Rd:TD 0 0 0.67 . 0.67 . . . 
Rd:VD 0 0 1.0404 . 1.0404 . . . 
Rd:VMP 0 0 1.1208 . 1.1208 . . . 
Rd:VMPT-VT 0 0 1.9401 . 1.9401 . . . 
Rd:VRd 1 1 1.4039 1.4039 . . . . 
Rd:VTD 0 0 1.2082 . 1.2082 . . . 
Rd:VTP 0 0 0.8927 . 0.8927 . . . 
Rd18:TD 0 0 0.8398 . 0.8398 . . . 
Rd18:VD 0 0 1.3039 . 1.3039 . . . 
Rd18:VMP 0 0 1.4047 . 1.4047 . . . 
Rd18:VMPT-VT 0 0 2.4317 . 2.4317 . . . 
Rd18:VRd 0 0 1.7596 . 1.7596 . . . 
Rd18:VTD 0 0 1.5143 . 1.5143 . . . 
Rd18:VTP 0 0 1.1188 . 1.1188 . . . 
VD:TD 0 0 0.644 . 0.644 . . . 
VMP:TD 0 0 0.5978 . 0.5978 . . . 
VMPT-VT:TD 0 0 0.3453 . 0.3453 . . . 
VRd:TD 0 0 0.4772 . 0.4772 . . . 
VTD:TD 0 0 0.5545 . 0.5545 . . . 
VTP:TD 0 0 0.7506 . 0.7506 . . . 
VMP:VD 1 1 0.9283 0.8969 . . . . 
VMPT-VT:VD 0 0 0.5362 . 0.5362 . . . 
VRd:VD 0 0 0.741 . 0.741 . . . 
VTD:VD 1 1 0.8611 0.8932 . . . . 
VTP:VD 0 0 1.1654 . 1.1654 . . . 
VMP:VMPT-VT 1 1 1.7311 1.7311 . . . . 
VMP:VRd 0 0 1.2526 . 1.2526 . . . 
VMP:VTD 1 1 1.078 1.119 . . . . 
VMP:VTP 1 1 0.7965 0.7965 . . . . 
VMPT-VT:VRd 0 0 0.7236 . 0.7236 . . . 
VMPT-VT:VTD 0 0 0.6227 . 0.6227 . . . 
VMPT-VT:VTP 0 0 0.4601 . 0.4601 . . . 
VRd:VTD 0 0 0.8606 . 0.8606 . . . 
VRd:VTP 0 0 0.6358 . 0.6358 . . . 
VTP:VTD 0 0 1.3535 . 1.3535 . . . 








Appendix 8 Results scenario analysis 2  
Table Results scenario 2  
 
HR obtained by Weisel et 
al. HR scenario analysis 2 
 HR 95% CrI HR 95% CI 
Rd v MP 0.39 [0.31-0.50] 0.41 [0.32-0.52] 
Rd v MPT 0.69 [0.59-0.80] 0.72 [0.61-0.85] 
Rd v VMP 0.7 [0.49-0.99] 0.73 [0.48-1.11] 
 
Figure Forestplot scenario 2  
 
Appendix 9 Figure Results scenario fixed effect model  
 
 
 
